Pull incentives for antibiotics: Duke-Margolis PAVE policy paper and PBS Newshour segments

Dear All: 

We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this!

Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to the voices calling for new economic models for antibiotics.

First, the Duke-Margolis Center for Health Policy has released both a White Paper and a viewpoint paper in JAMA describing the elements of a Priority Antimicrobial Value and Entry (PAVE) Award proposal that could be a path for the diverse and complex US market to create such a model. PAVE combines a market entry reward with population-based payments from public and private payers that phase in over time.

Second, PBS Newshour is doing a Stopping Superbugs series in which their science and economic correspondents have collaborated to tell this story. The first three episodes are out:

2 Aug 2017: We are running out of effective antibiotics
3 Aug 2017: The financial barrier
4 Aug 2017: Is there an economic cure for the problem?

We have yet to turn any of this into concrete action, but steadily expanding the conversational echo chamber is a necessary prelude to such action. I’m looking forward to the rest of the PBS broadcasts, and then next up, I think, will be the output from DRIVE-AB in early September. Stay tuned!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top